Trial Profile
Retrospective, multicenter study of 12-week ombitasvir/paritaprevir/ritonavir therapy included genotype 1b patients with non-dialysis chronic kidney disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C; Kidney disorders
- Focus Therapeutic Use
- 22 Jul 2018 New trial record
- 01 Jun 2018 Results published in the Hepatology Research